TFPI-2

TFPI-2

TFPI-2 Informations sur la molécule

Molecule Name
DNA-(apurinic or apyrimidinic site) lyase
Alias de la molécule
TFPI2,PP5,REF1
Drug Development Progress
Nombre de médicaments cliniques1
Nombre de médicaments commercialisés0
Phase de R&D la plus avancéePhase 2 Clinical
Alias de la cible
AP endonuclease 1,DNA-(apurinic or apyrimidinic site) lyase,APE1,APEN,REF-1,Apurinic-apyrimidinic endonuclease 1,APEX nuclease,REF1,APEX,APEX1,Apurinic/Apyrimidinic Endodeoxyribonuclease 1,APEX Nuclease (Multifunctional DNA Repair Enzyme) 1,Redox Factor-1,HAP1,APE,APX,APEX Nuclease (Multifunctional DNA Repair Enzyme),Deoxyribonuclease (Apurinic Or Apyrimidinic),Apurinic/Apyrimidinic (Abasic) Endonuclease,AP Endonuclease Class I,Protein REF-1,AP Lyase,APE-1,DNA-(apurinic or apyrimidinic site) endonuclease
Contexte de la molécule
Tissue Factor Pathway Inhibitor 2 (TFPI­2) is also known as placental protein 5 (PP5) and retinal pigment epithelial cell factor 1 (REF­1), is a member of the Kunitz-type serine proteinase inhibitor family, is a structural homologue of tissue factor pathway inhibitor (TFPI). TFPI2 is highly abundant in the full-term placenta and widely expressed in umbilical vein endothelial cells, liver, placenta, heart, pancreas, and maternal serum at advanced pregnancy. TFPI­2 may play a role in the regulation of plasmin-mediated matrix remodeling. Inhibits trypsin, plasmin, factor VIIa/tissue factor and weakly factor Xa and has no effect on thrombin. Reduced synthesis of TFPI-2 has been related to numerous pathophysiological processes such as inflammation, angiogenesis, atherosclerosis, retinal degeneration and tumor growth / metastasis.

TFPI-2 Liste de produits

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
APX-3330APX-3330; APX3330; E-3330Phase 2 ClinicalEisai Co Ltd
Solid tumours; Inflammatory Bowel Diseases; Neoplasms; Diabetic macular oedema; Diabetic Retinopathy
Details